bioRxivCancer BiologyPreprint
Interferon restores replication fork stability and cell viability in BRCA-defective cells via ISG15
L. Penengo, U. Biswas, R. N. Moro, S. S. Kharat, P. Das, A. R. Chaudhuri, S. K. Sharan
Abstract
DNA replication and repair defects or genotoxic treatments trigger interferon (IFN)-mediated inflammatory responses. However, whether and how IFN signaling in turn impacts the DNA replication process has remained elusive. Here we show that IFN promotes replication fork stability, cell proliferation and survival in BRCA1/2-defective cancer cells and rescues the lethality of BRCA2-deficient mouse embryonic stem cells. Although IFN activates hundreds of genes, these effects are specifically mediated by the ubiquitin-like modifier ISG15 (IFN-stimulated gene 15). Inactivation of ISG15 or of the enzymes promoting its conjugation, referred as ISGylation, completely suppresses the impact of IFN on the replication process. Depletion of ISG15 significantly reduces cell proliferation rates whereas its upregulation results in increased resistance to the chemotherapeutic drug cisplatin in human BRCA1-mutated triple-negative and mouse BRCA2-deficient breast cancer cells, respectively. Accordingly, cells carrying BRCA1/2 defects consistently show increased ISG15 levels, representing a novel, in-built mechanism of drug resistance linked to BRCAness.
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- assay: proteomics
- research focus: drug response / drug discovery
- research focus: cell type annotation
- research focus: differential expression
- approach: genetic perturbation / CRISPR
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- IFI16 senses and protects stalled replication forks
Amelia Gamble, Thomas A. Ward, … Christopher J. Staples·Molecular CellPeer-reviewed·Jan 1, 2026
- TAOK1 regulates chemo- and radiosensitivity in BRCA1/2-deficient tumors
Lea Lingg, Merve Mutlu, … Paola Francica·bioRxiv·Oct 14, 2025
- IGF targeting perturbs global replication through ribonucleotide reductase dysfunction
G. Rieunier, X. Wu, … V. M. Macaulay·bioRxiv·Aug 11, 2020
- BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
T. Reislander, E. Puig Lombardi, … M. Tarsounas·bioRxiv·Dec 10, 2018
- PARPi triggers STING-dependent immune response and enhances therapeutic efficacy of immune checkpoint blockade independent of BRCAness
- H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours
D. Dibitetto, M. Liptay, … S. Rottenberg·bioRxiv·May 22, 2023